Abrocitinib is an oral, selective Janus kinase 1 (JAK1) inhibitor approved for moderate-to-severe atopic dermatitis, working by dampening cytokine-driven inflammatory signalling implicated in disease pathogenesis. As a relatively recent JAK-inhibitor entrant, robust reference material is essential for emerging generic and analytical development. Simson Pharma offers an Abrocitinib reference standard and impurities to meet this growing need.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Abrocitinib Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.
